Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Alzheimer's Disease

  Free Subscription


Articles published in BMJ

Retrieve available abstracts of 23 articles:
HTML format



Single Articles


    February 2021
  1. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    PubMed     Abstract available


    October 2020
  2. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    PubMed    


    December 2019
  3. JOE E, Ringman JM
    Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
    BMJ. 2019;367:l6217.
    PubMed     Abstract available


    October 2019
  4. HAWKES N
    FDA considers Alzheimer's drug previously abandoned for lack of effectiveness.
    BMJ. 2019;367:l6164.
    PubMed    


    March 2019
  5. IACOBUCCI G
    Long term hormone therapy may increase Alzheimer's risk, study finds.
    BMJ. 2019;364:l1050.
    PubMed    


  6. SAVOLAINEN-PELTONEN H, Rahkola-Soisalo P, Hoti F, Vattulainen P, et al
    Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.
    BMJ. 2019;364:l665.
    PubMed     Abstract available


  7. MAKI PM, Girard LM, Manson JE
    Menopausal hormone therapy and cognition.
    BMJ. 2019;364:l877.
    PubMed    


    September 2018
  8. BRAILLON A, Wilson M
    Does moderate alcohol consumption really have health benefits?
    BMJ. 2018;362:k3888.
    PubMed    


    August 2018
  9. HAWKES N
    Alzheimer's disease: researcher behind "new test" paper tried to silence critics.
    BMJ. 2018;362:k3444.
    PubMed    


    March 2018
  10. MAYOR S
    Alzheimer's disease research: five minutes with John Hardy.
    BMJ. 2018;360:k1163.
    PubMed    


    January 2018
  11. HAWKES N
    Pfizer abandons research into Alzheimer's and Parkinson's diseases.
    BMJ. 2018;360:k122.
    PubMed    


    December 2017
  12. LARSSON SC, Traylor M, Malik R, Dichgans M, et al
    Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis.
    BMJ. 2017;359:j5375.
    PubMed     Abstract available


  13. SOMMERLAD A, Livingston G
    Preventing Alzheimer's dementia.
    BMJ. 2017;359:j5667.
    PubMed    


    June 2017

  14. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
    BMJ. 2017;357:j3170.
    PubMed    


  15. TORJESEN I
    Proton pump inhibitor use does not raise dementia and Alzheimer's risk, study suggests.
    BMJ. 2017;357:j3063.
    PubMed    


    April 2017
  16. BENN M, Nordestgaard BG, Frikke-Schmidt R, Tybjaerg-Hansen A, et al
    Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
    BMJ. 2017;357:j1648.
    PubMed     Abstract available


  17. WISE J
    Vascular risk factors show link to development of Alzheimer's.
    BMJ. 2017;357:j1847.
    PubMed    


    February 2017
  18. HAWKES N
    Merck ends trial of potential Alzheimer's drug verubecestat.
    BMJ. 2017;356:j845.
    PubMed    


    December 2016
  19. LE COUTEUR DG, Hunter S, Brayne C
    Solanezumab and the amyloid hypothesis for Alzheimer's disease.
    BMJ. 2016;355:i6771.
    PubMed    


  20. MAYOR S
    Statins are linked to reduced Alzheimer's risk, study finds.
    BMJ. 2016;355:i6675.
    PubMed    


    November 2016
  21. HAWKES N
    Sixty seconds on . . . solanezumab.
    BMJ. 2016;355:i6389.
    PubMed    


  22. HAWKES N
    Promise of new Alzheimer's drug is dashed after lack of evidence.
    BMJ. 2016;355:i6362.
    PubMed    


    January 2016
  23. HOPKINS TANNE J
    Approved drugs are to be studied for use in Alzheimer's disease.
    BMJ. 2016;354:i5063.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: